Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...
-
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at 2026 AAD
-
NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that on March 25, 2026, the Company received a notice from the staff of NYSE...
-
Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its...
-
Company announcement no. 7 – 26 27 March 2026 NTG Nordic Transport Group A/S – Annual General Meeting 2026 Today, at 14:00, NTG Nordic Transport Group A/S (“NTG” or the “Company”), CVR no. 12 54 61...
-
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...
-
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an...
-
Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and...
-
Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-marketStockholders will receive one share of First Tracks Bio common stock for every one...
-
Inclusive of $80 million in proceeds from private placement by leading investorsFirst Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 ...